几类炎症评分评估肝细胞癌切除术后预后价值研究进展
Research Progress in Evaluating the Value of Several Types of Inflammation Scores after Liver Cell Resection Surgery
DOI: 10.12677/ACM.2023.1371567, PDF,   
作者: 马海魁, 王海久*：青海大学附属医院肝胆外科，青海 西宁
关键词: 肝细胞癌；肝脏炎症评分；分级；预后；Hepatocellular Carcinoma； Liver Inflammation Score； Grade； Prognosis
摘要: 肝细胞癌(HCC)是世界范围内第五比较常见的癌症和第三常见的癌症死亡原因。我国肝细胞癌的发病率和死亡率均居世界第一位。现在对肝细胞癌的治疗方法有很多，手术切除是肝细胞癌的首选治疗方式，但其预后仍不理想。HCC切除后，预后取决于肿瘤大小和分化程度、血管侵犯和切缘状况等因素。这些因素大部分只有在手术后才能确定。现阶段新兴的几种肝脏炎症评分是可以在手术前预测肝癌预后的潜在指标，大致包括白蛋白–胆红素分级(ALBI)、血小板–白蛋白–胆红素分级(PALBI)、白蛋白–吲哚箐绿评分(ALICE)、甲胎蛋白联合纤维蛋白原与白蛋白比值评分(A-FAR)、天冬氨酸转氨酶与血小板的比值指数(APRL)。本文将阐述以上几类炎症评分对肝癌患者预后预测价值的研究进展做一综述。
Abstract: Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer death worldwide. The incidence rate and mortality rate of hepatocellular carcinoma in China rank first in the world. There are many treatments for HCC, and surgical resection is the first choice for HCC, but its prognosis is still not ideal. After HCC resection, the prognosis depends on fac-tors such as tumor size and degree of differentiation, vascular invasion and resection margin status. Most of these factors can be determined only after surgery. At this stage, several emerging liver in-flammation score are potential indicators to predict the prognosis of liver cancer before surgery, in-cluding albumin-bilirubin grade (ALBI), platelet-albumin-bilirubin grade (PALBI), albumin-green score (ALICE), alpha fetoprotein combined fibrinogen to albumin ratio score (A-FAR), aspartate transaminase to platelet ratio index (APRL). This paper will summarize the progress of the predic-tive value of liver cancer patients.
文章引用：马海魁, 王海久. 几类炎症评分评估肝细胞癌切除术后预后价值研究进展[J]. 临床医学进展, 2023, 13(7): 11221-11226. https://doi.org/10.12677/ACM.2023.1371567

参考文献

[1] Corwin, M.T., Lee, A.Y., et al. (2017) Nonstandardized Terminology to Describe Focal Liver Lesions in Patients at Risk for Hepatocellular Carcinoma: Implications Regarding Clinical Communication. American Journal of Roentgenology, 210, 85-90. [Google Scholar] [CrossRef] 
[2] Ao, L., Song, X.K., Li, X.Y., Tong, M.S., et al. (2016) An Individualized Prognostic Signature and Multi-Omics Distinction for Early Stage Hepatocellular Carcinomapatients with Surgical Resection. Oncotarget, 7, 24097-24110. [Google Scholar] [CrossRef] [PubMed]
[3] Johnson, P.J., Berhane, S., Kagebayashi, C., Satomura, S., Teng, M., et al. (2014) Assessment of Liver Function in Patients with Hepatocellular Carcinoma: A New Evidence-Based Ap-proach—The ALBI Grade. Journal of Clinical Oncology, 33, 550-558. [Google Scholar] [CrossRef] 
[4] Chen, R.C., Cai, Y.J., Wu, J.M., Wang, X.D., Song, M., et al. (2016) Usefulness of Albumin-Bilirubin Grade for Evaluation of Long-Term Prognosis for Hepatitis B-Related Cirrho-sis. Journal of Viral Hepatitis, 24, 238-245. [Google Scholar] [CrossRef] [PubMed]
[5] Cho, W.R., Hung, C.H., Chen, C.H., Lin, C.C., Wang, C.C., et al. (2020) Ability of the Post-Operative ALBI Grade to Predict the Outcomes of Hepatocellular Carcinoma after Curative Surgery. Scientific Reports, 10, Article No. 7290. [Google Scholar] [CrossRef] [PubMed]
[6] Chan, A.W.H., Kumada, T., Toyoda, H., Tada, T., Chong, C.C.N., et al. (2016) Integration of Albumin-Bilirubin (ALBI) Score into Barcelona Clinic Liver Cancer (BCLC) System for Hepatocellular Carcinoma. Journal of Gastroenterology and Hepatology, 31, 1300-1306. [Google Scholar] [CrossRef] [PubMed]
[7] Chan, A.W.H., Leung, H.H.W., Chong, C.C.N. and Chan, S.L. (2016) Validating the ALBI Grade: Its Current and Future Use in HCC Prognostication. Journal of Hepatology, 66, 661-663. [Google Scholar] [CrossRef] [PubMed]
[8] Cucchetti, A., Ercolani, G., Vivarelli, M., Cescon, M., Ravaioli, M., et al. (2009) Is Portal Hypertension a Contraindication to Hepatic Resection? Annals of Surgery, 250, 922-928. [Google Scholar] [CrossRef] 
[9] Takemura, N., Takemura, N., Aoki, T., Hasegawa, K., Kaneko, J., et al. (2019) Hepatectomy for Hepatocellular Carcinoma after Perioperative Management of Portal Hyperten-sion. The British Journal of Surgery, 106, 1066-1074. [Google Scholar] [CrossRef] [PubMed]
[10] Sonohara, F., Yamada, S., Tanaka, N., Tashiro, M., Sunagawa, Y., et al. (2019) Comparison of Non-Invasive Liver Reserve and Fibrosis Models: Implications for Surgery and Prognosis for Hepatocellular Carcinoma. Hepatology Research: The Official Journal of the Japan Society of Hepatology, 49, 1305-1315. [Google Scholar] [CrossRef] [PubMed]
[11] Wang, Z.X., Wang, Z.X., Peng, W., Zhang, X.Y., Wen, T.F., et al. (2021) Prognostic Significance of Postoperative Change of PALBI Grade for Patients with Hepatocellular Carci-noma after Hepatectomy. Medicine, 100, e24476. [Google Scholar] [CrossRef] 
[12] Zou, H., Wen, Y., Yuan, K., Miao, X.Y., Xiong, L., et al. (2017) Combining Albumin-Bilirubin Score with Future Liver Remnant Predicts Post-Hepatectomy Liver Failure in HBV-Associated HCC Patients. Liver International, 38, 494-502. [Google Scholar] [CrossRef] [PubMed]
[13] Kokudo, T., Kokudo, T., Hasegawa, K., Amikura, K., Uldry, E., et al. (2016) Assessment of Preoperative Liver Function in Patients with Hepatocellular Carcinoma—The Albumin-Indocyanine Green Evaluation (ALICE) Grade. PLOS ONE, 11, e0159530. [Google Scholar] [CrossRef] [PubMed]
[14] Russolillo, N., Forchino, F., Conci, S., Mele, C., Langella, S., et al. (2019) Validation of the Albumin-Indocyanine Green Evaluation Model in Patients with Resected Hepatocellular Car-cinoma and Comparison with the Albumin-Bili- rubin Score. Journal of Hepato-Biliary-Pancreatic Sciences, 26, 51-57. [Google Scholar] [CrossRef] [PubMed]
[15] Hiraoka, A., Kumada, T., Kudo, M., Hirooka, M., Tsuji, K., et al. (2017) Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. Liver Cancer, 6, 204-215. [Google Scholar] [CrossRef] [PubMed]
[16] Wang, Y.K., Bi, X.Y., Li, Z.Y., Zhao, H. and Zhao, J.J. (2017) A New Prognostic Score System of Hepatocellular Carcinoma following Hepatectomy. Chinese Journal of Oncology, 39, 903-909. (In Chinese)
[17] Ridker, P.M., Howard, C.P., Walter, V., Everett, B., Libby, P., et al. (2012) Effects of Inter-leukin-1β Inhibition with Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen: A Phase IIb Randomized, Placebo-Controlled Trial. Circulation, 126, 2739-2748. [Google Scholar] [CrossRef] 
[18] 刘益民, 贾坤林, 徐翠容, 蒋叙川, 赖永才. 血清白蛋白、前白蛋白水平对非小细胞肺癌患者预后的影响[J]. 标记免疫分析与临床, 2018, 25(2): 232-235.
[19] Zhang, L., Chen, Q.G., Li, S.Q., Zhang, J., Min, Q.H., et al. (2018) Preoperative Fibrinogen to Prealbu-min Ratio as a Novel Predictor for Clinical Outcome of Hepatocellular Carcinoma. Future Oncology, 15, 13-22. [Google Scholar] [CrossRef] [PubMed]
[20] 范龙飞, 刘双池, 段家康, 秦中强, 谈燚. 甲胎蛋白联合纤维蛋白原与白蛋白比值评分系统在肝细胞癌预后中的应用价值[J]. 牡丹江医学院学报, 2020, 41(4): 10-14. [Google Scholar] [CrossRef] 
[21] Wai, C.T., Greenson, J.K., Fontana, R.J., Kalbfleisch, J.D., Marrero, J.A., et al. (2003) A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Pa-tients with Chronic Hepatitis C. Hepatology, 38, 518-526. [Google Scholar] [CrossRef] [PubMed]
[22] Raftopoulos, S.C., George, J., Bourliere, M., Rossi, E., de Boer, W.B., et al. (2011) Comparison of Noninvasive Models of Fibrosis in Chronic Hepatitis B. Hepatology International, 6, 457-467. [Google Scholar] [CrossRef] [PubMed]
[23] 麦荣云, 曾洁, 叶甲舟, 等. 术前天冬氨酸转氨酶与血小板比值指数预测原发性肝癌肝切除术后肝衰竭的价值[J]. 第二军医大学学报, 2019, 40(1): 61-67. [Google Scholar] [CrossRef] 
[24] 王越, 刘学民, 王博, 等. 术前天冬氨酸转氨酶/血小板比值指数对肝细胞癌患者手术切除后并发症的预测价值[J]. 中华肝胆外科杂志, 2016, 22(5): 289-293. [Google Scholar] [CrossRef] 
[25] Cheng, J.W., Zhao, P., Liu, J.B., Liu, X. and Wu, X.L. (2016) Preoperative Aspartate Aminotransferase-to-Platelet Ratio Index (APRI) Is a Predictor on Postoperative Outcomes of Hepatocellular Carcinoma. Medicine, 95, e5486 [Google Scholar] [CrossRef] 

为你推荐